Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) announced that President and CEO Todd C. Brady, M.D., Ph.D. will participate in fireside conversations at two upcoming conferences: the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 9:20 a.m. ET. These events will be archived on the company's Investor & Media page for 90 days after the presentations. Aldeyra focuses on developing therapies for immune-mediated diseases.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that President and Chief Executive Officer Todd C. Brady, M.D., Ph.D. will participate in analyst-led fireside conversations at the H.C. Wainwright Global Life Sciences Conference and the Oppenheimer 31st Annual Healthcare Conference.

• H.C. Wainwright Global Life Sciences Conference
  Date: Tuesday, March 9, 2021
  Time: 7:00 a.m. ET

• Oppenheimer 31st Annual Healthcare Conference
  Date: Tuesday, March 16, 2021
  Time: 9:20 a.m. ET

To view these events, please visit the Investor & Media page of the company’s website. After the presentations, the events will remain archived on the website for 90 days.

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005108/en/

FAQ

What is Aldeyra Therapeutics' participation in the H.C. Wainwright Conference?

Aldeyra Therapeutics will have President and CEO Todd C. Brady participate in the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET.

When is Aldeyra presenting at the Oppenheimer Healthcare Conference?

Aldeyra Therapeutics will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 9:20 a.m. ET.

Where can I find the archived presentations from Aldeyra's events?

The archived presentations will be available on Aldeyra's Investor & Media page for 90 days after the respective events.

What are the main therapies being developed by Aldeyra Therapeutics?

Aldeyra Therapeutics is developing therapies like reproxalap for dry eye disease, ADX-629 for immune-mediated diseases, and ADX-2191 for proliferative vitreoretinopathy.

What is the focus of Aldeyra Therapeutics as a clinical-stage biotechnology company?

Aldeyra focuses on developing novel therapies to improve the lives of patients with immune-mediated diseases.